Never smokers with lung cancer: Analysis of genetic variants

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 10, 2011, Pages 2807-2809

  Xiao, Haijun ^a   Ding, Jie ^b   Gao, Shan ^a   Yang, Shujuan ^c   Huang, Yuchuan ^d,e  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

^b TIANJIN UNION MEDICAL CENTER   (China)

^c SICHUAN UNIVERSITY   (China)

^d China Tobacco Chuanyu Industrial Corporation   (China)

^e SICHUAN UNIVERSITY   (China)

Author keywords

China; Genetic variants; Lung cancer; Non; Smokers

Indexed keywords

EID: 84863270506     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Darby S, Hill D, Auvinen A, et al (2005). Radon in homes and risk of lung cancer: collaborative analysis of individual data from 13 European case-control studies. BMJ, 330, 223.
2. Doll R, Hill AB (1950). Smoking and carcinoma of the lung: Preliminary report. BMJ, 2, 739-48.
3. Gealy R, Zhang L, Siegfried JM, Luketich JD, Keohavong P (2001).Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women. Cancer Epidemiology Biomarkers Prev, 8, 297-302,1999; Erratum in: Cancer Epidemiology Biomarkers Prev, 10, 1309.
4. Girard N, Lou E, Azzoli CG, et al (2010). Analysis of genetic variants in never-smokers with lung cancer facilitated by an internet-based blood collection protocol: a preliminary report. Clinical Cancer Research, 16, 755-63.
5. Greenblatt MS, Bennett W P, Hollstein M, Harris CC(1994). Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Research, 4, 4855-78.
6. Hagiwara N, Mechanic LE, Trivers GE, et al (2006). Quantitative detection of p53 mutations in plasma DNA from tobacco smokers. Cancer Research, 66, 8309-17.
7. Hainaut P, Hernandez T, Robinson A, et al (1998). IARC database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualization tools. Nucleic Acids Reseach, 26, 205-13.
8. Hainaut P, Pfeifer GP (2001). Patterns of p53 G3T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. Carcinogenesis, 22, 367-74.
9. Harris CC (1996). p53 tumor suppressor gene: at the crossroads of molecular carcinogenesis, molecular epidemiology, and cancer risk assessment. Environ Health Perspect, 104, 435-9.
10. Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991). p53 mutations in human cancers. Science, 253, 49-53.
11. Huang RJ, Boffetta P, Brockmoller J, et al (2003). CYP1A1 and GSTM1 genetic polymorphisms and lung cancer risk in Caucasian non-smokers: a pooled analysis. Carcinogenesis, 24, 875-82.
12. Husgafvel-Pursiainen K, Boffetta P, Kannio A, et al (2000). p53 mutations and exposure to environmental tobacco smoke in a multicenter study on lung cancer. Cancer Res, 60, 2906-11.
13. Hussain SP, Harris CC (1998). Molecular epidemiology of human cancer: contribution of mutation spectra studies of tumor suppressor genes. Cancer Research, 58, 4023-37.
14. Janjijian Y, Kris MG, Miller VA, Riely G (2008). Pack years of cigarette smoking as a predictor of survival in 2,010 patients with stage IIIb/IV nonsmall cell lung cancer (NSCLC). J Clin Oncol, 26, 8005.
15. Janne PA, Engelman JA, Johnson BE (2005). Epidermal growth factor receptor mutations in non-small cell lung cancer: Implications for treatment and tumor biology. J Clin Oncol, 23, 3227-34.
16. Jou YS, Lo YL, Hsiao CF, et al (2009). Association of an EGFR intron 1 SNP with never-smoking female lung adenocarcinoma patients. Lung Cancer, 64, 251-6.
17. Koo LC, Ho JH (1990). Worldwide epidemiological patterns of lung cancer in nonsmokers. Internal J Epidemiology, 19, S14-23.
18. Kurahashi N, Inoue M, Liu Y, et al (2008). Passive smoking and lung cancer in Japanese non-smoking weomen: a prospective study. Int J Cancer, 122, 653-7.
19. Lee DH, Han Ji-Youn, Lee HG, et al (2005). Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smoker. Clin Cancer Res 11, 3032-7.
20. Levine AJ (1997). p53, the cellular gatekeeper for growth and division. Cell, 88, 323-31.
21. Lynch TJ, Bell DW, Sordella R, et al (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. New Eng J Med, 350, 2129-39.
22. Paez JG, Janne PA, Lee JC, et al (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 304, 1497-500.
23. Pao W, Miller VA (2005). Epidermal growth factor receptor mutations, small molecule kinase inhibitors, and non-small cell lung cancer: Current knowledge and future directions. J Oncology, 23, 2556-68.
24. Pao W, Miller V, Zakowski M, et al (2004). EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA, 101, 13306-11.
25. Parkin DM, Pisani P, Lopez AD, Masuyer E (1944). At least one in seven cases of cancer is caused by smoking: Global estimates for 1985. Int J Cancer, 59, 494-504.
26. Raimondi S, Boffetta P, Anttila S, et al (2005). Metabolic gene polymorphisms and lung cancer risk in non-smokers an update of the GSEC study. Mutat Res, 592, 45-47.
27. Rudin CM, Avila-Tang E, Harris CC, et al (2009). Lung cancer in never smokers: molecular profile and therapeutic implications. Clin Cancer Res, 15, 5646-61.
28. Shigematsu H, Lin L, Takahashi T, et al (2005). Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J of the National Cancer Institute, 97, 339-46.
29. Sidransky D, Hollstein M (1996). Clinical implications of the p53 gene. Annual Review Medicine, 47, 285-301.
30. Toh CK, Gao F, Lim WT, et al (2006). Never smokers with lung cancer: epidemiologic evidence of a distinct disease entity. J of Clinical Oncology, 24, 2245-51.
31. Wakelee HA, Chang ET, Gomez SL, et al (2007). Lung cancer incidence in never smokers. J Clin Oncol, 25, 472-8.
32. Wynder EL, Graham EA(1985). Tobacco smoking as a possible etiologic factor in bronchiogenic carcinoma: A study of six hundred and eighty-four proved cases. J Am Medical Assoc, 253, 2986-94.